Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
PlainTrials
RecruitingPhase 4interventionalRules rewrite

Phase 4: testing Atogepant 60 mg for Migraine

This goal of this study is to compare three medications used for migraine preventive treatment. This study will compare atogepant, a newer migraine preventive medication, with two older preventive medications, topiramate and propranolol.

Official registry: https://clinicaltrials.gov/study/NCT06972056 · Mayo Clinic · enrollment listed as 1,335

What this phase means

Phase 4: the treatment is already approved. This study asks new questions — longer-term effects, other diseases, or how it compares in everyday care.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are Atogepant 60 mg, Propranolol 160 mg, or Topiramate 100 mg. The registry lists allocation as randomized. This goal of this study is to compare three medications used for migraine preventive treatment.

They plan to enroll about 1,335 people at 37 sites. Taking part typically means taking a study drug (or dummy pill) plus check-ins.

Official title (unrewritten)

A Comparative Effectiveness Study of Oral Medications Used for Migraine Prevention: The APT Comparison Study

Interventions: Atogepant 60 mg, Propranolol 160 mg, Topiramate 100 mg

Primary outcome (registry wording): Treatment Responder (atogepant vs. topiramate; atogepant vs. propranolol)

Who it is for (from inclusion criteria)

  • Ages 18 Years to 70 Years
  • Adults, 18-70 years of age at the time of enrollment
  • Migraine with aura, migraine without aura, and/or chronic migraine; according to ICHD-3 diagnostic criteria. (Those with daily or continuous headaches are not excluded.)
  • Migraine onset prior to 50 years of age
  • Migraine present for at least 12 months at the time of enrollment
  • If already taking a migraine preventive treatment, willing to continue with that treatment without dose change during the first 16 weeks of the study, including the 4-week run-in phase and 12-week randomly assigned phase
  • Not pregnant or breastfeeding
  • Women of childbearing potential must agree to use effective methods of contraception to reduce the risk of pregnancy

Public study contact (from the registry)

Michael R Leonard, MDiv

480-342-2908

ARZAPTTrial@mayo.edu

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

37 listed

Related recruiting trials in this snapshot

FAQ about this NCT record

Is NCT06972056 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT06972056?

Phase 4. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT06972056?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary